Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$3.14 -0.06 (-1.88%)
Closing price 04:10 PM Eastern
Extended Trading
$3.16 +0.02 (+0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Advanced

Key Stats

Today's Range
$3.14
$3.24
50-Day Range
$2.36
$3.20
52-Week Range
$0.90
$3.24
Volume
16,965 shs
Average Volume
89,473 shs
Market Capitalization
$113.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ARMP MarketRank™: 

Armata Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    Armata Pharmaceuticals has a consensus price target of $9.00, representing about 185.2% upside from its current price of $3.16.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Armata Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.26% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 24.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.26% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 24.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Armata Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

  • Read more about Armata Pharmaceuticals' insider trading history.
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARMP Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
See More Headlines

ARMP Stock Analysis - Frequently Asked Questions

Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP stock has increased by 57.8% and is now trading at $3.1560.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The firm earned $1.23 million during the quarter, compared to the consensus estimate of $0.90 million.

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

Last Earnings
11/14/2023
Today
10/07/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:ARMP
CIK
921114
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+185.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.92 million
Net Margins
-374.30%
Pretax Margin
-374.30%
Return on Equity
N/A
Return on Assets
-24.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.06
Quick Ratio
0.06

Sales & Book Value

Annual Sales
$5.17 million
Price / Sales
22.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.33) per share
Price / Book
-2.37

Miscellaneous

Outstanding Shares
36,230,000
Free Float
5,616,000
Market Cap
$114.34 million
Optionable
Not Optionable
Beta
1.12
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NYSEAMERICAN:ARMP) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners